Daniel O'Day
Daniel O'Day is the CEO of Gilead Sciences, a biopharmaceutical company known for its innovative treatments for various diseases, including HIV. Under his leadership, Gilead has made significant advancements in the development of antiviral therapies, including the recent approval of Yeztugo, a promising new injectable treatment for the prevention of HIV. O'Day has been a key figure in the biotech industry, advocating for accessible healthcare solutions and emphasizing the importance of addressing global health challenges.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Kenya | 1 | 8.00 | 0.09% | +0% | 53,771,296 | 48,225 | $106,000 | 95$ |
| Totals | 1 | 53,771,296 | 48,225 | $106,000 | 95$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Kenya:
Daniel O'Day, Gilead Sciences' chairman and CEO, said efforts were underway to authorize distribution of the drug.
8
Ghana:
Gilead Chairman and CEO Daniel O’Day announced that the company is providing lenacapavir at no profit to reach up to two million people.
8
United States:
Gilead Chairman and CEO Daniel O’Day announced that the company is providing lenacapavir at no profit to reach up to two million people.
8
Guyana:
Gilead CEO Daniel O’Day expressed hope that U.S. aid spending to fight the epidemic will resume.
7
Kenya:
Gilead chairman and chief executive Daniel O'Day said in a statement.
8
Slovakia:
Daniel O'Day is the chairman and CEO of Gilead Sciences, who stated that the approval of the injection is a historic day in the fight against HIV.
9
Portugal:
Daniel O'Day, president and CEO of Gilead, considered the approval a 'decisive moment in the decades-long fight against HIV'.
9
Peru:
Daniel O'Day, president and CEO of Gilead, described the approval as a 'key moment in the decades-long fight against HIV'.
9
Mozambique:
Daniel O'Day, president and CEO of Gilead, considered the approval a 'decisive moment in the decades-long fight against HIV'.
9
Cabo Verde:
Daniel O'Day, president and CEO of Gilead, considered the approval a 'decisive moment in the decades-long fight against HIV'.
9